Summary
Pathological and biochemical evidence reviewed favours the hypothesis that the dementia seen in Parkinson’s disease, particularly after long-term levodopa therapy, is akin to Alzheimer’s disease. We postulate, in late Parkinson’s disease, the development of a relative cholinergic deficiency due to the accelerated process of aging and the presence of neurofibrillary tangles (with choline acetyl transferase deficiency). This process would be enhanced by the imbalance in favour of dopaminergic predominance caused by chronic levodopa therapy, and would partially explain the increase in dementia. As a test of this hypothesis we have given 10 levodopa-treated parkinsonian patients with dementia, a regimen of lecithin (average 20 gms/day). A clear improvement in Kohs block design test of constructive ability was noted with a decrease in the toxic symptoms of confusion, hallucinations and nightmares. In another study lecithin produced a decrease in levodopa-induced abnormal movements, but at the expense of motor Performance. These preliminary investigations indicate that the progressive dementia of Parkinson’s disease may not be irreversible.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barbeau, A.: Biochemistry of Parkinson’s disease. Excerpta Medica Int. Congr. Ser. 38, 152–153 (1961).
Barbeau, A.: The pathogenesis of Parkinson’s disease: a new hypothesis. Can. Med. Ass. J. 87, 802–807 (1962).
Barbeau, A.: The clinical physiology of side-effects in long-term L-DOPA therapy. In: Advances in Neurology, Vol. 5 (McDowell, F. FL., Barbeau, A., eds.), pp. 347–365. New York: Raven Press. 1979.
Barbeau, A.: Neurological and Psychiatric side-effects of L-DOPA. In: Int. Encyclop. of Pharmacol. and Therap., Sect. 25 (Hornykiewicz, O., ed.), Vol. 1, pp. 475–494 (1976).
Barbeau, A.: Emerging treatments: replacement therapy with choline or lecithin in neurological diseases. Can. J. Neurol. Sci. 5, 157–160 (1978).
Becker, H., Schneider, E., Hacker, H., Fischer, P.A.: Cerebral atrophy in Parkinson’s disease-represented in CT. Arch. Psychiat. Nervenkr. 227, 81–88 (1979).
Birkmayer, W., Hornykiewicz, O.: Der L-Dioxyphenylalanin(DOPA-)– Effekt bei der Parkinson-Akinese. Wien. klin. Wschr. 73, 787–788 (1961).
Cohen, E. L., Wurtman, R. J.: Brain acetylcholine: increase after systemic choline administration. Life Sci. 16, 1095–1102 (1975).
Cohen, E. L., Wurtman, R. J.: Brain acetylcholine: control by dietary choline. Science 191, 561–562 (1976).
Davies, S. P., Maloney, A. J. F.: Selective loss of central cholinergic neurons in Alzheimers disease. Lancet 2, 1403 (1976).
Earnest, M. P., Heaton, R. K., Wilkinson, W. E., Manke, W. F.: Cortical atrophy, ventricular enlargement and intellectual impairment in the aged. Neurology (Minneap.) 29, 1138–1143 (1979).
Freedman, L. S., Ohuchi, T., Goldstein, M., Axelrod, F., Fish, I., Dancis, J.: Changes in human serum dopamine-β-hydroxylase activity with age. Nature (London) 236, 310–311 (1972).
Gottfries, C. G., Gottfries, I., Ross, B. E.: Homovanillic acid and 5-hydroxyindole acetic acid in cerebrospinal fluid related to rated mental and motor impairment in senile and presenile dementia. Acta Psychiat. Neurol. Scand. 46, 99–103 (1970).
Hakim, A. M., Mathieson, G.: Dementia in Parkinson’s disease: a neuropathologic study. Neurology (Minneap.) 29, 1209–1214 (1979).
McGeer, E. G., Fibiger, H. C., McGeer, P. L., Wickson, V.: Aging and brain enzymes. Experim. Gerontology 6, 391–396 (1971).
Samoroyski, T.: Central neurotransmitter substances and aging: a review. J. Am. Geriat. Soc. 25, 337–348 (1977).
Schneider, E., Becker, H., Fischer, P. A., Graw, H., Jacobi, P., Brinkmann, R.: The course of brain atrophy in Parkinson’s disease. Arch. Psychiat. Nervenkr. 227, 89–95 (1979 a).
Schneider, E., Fischer, P. A., Jacobi, P., Becker, H., Hacker, H.: The significance of cerebral atrophy for the symptomatology of Parkinson’s disease. J. neurol. Sci. 42, 187–197 (1979 b).
Wurtman, R. J., Hirsch, M. J., Growdon, J. H.: Lecithin consumption raises serum-free choline levels. Lancet 2, 68–69 (1977).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag
About this chapter
Cite this chapter
Barbeau, A. (1980). Lecithin in Parkinson’s Disease. In: Carlsson, A., Jellinger, K., Riederer, P. (eds) Current Topics in Extrapyramidal Disorders. Journal of Neural Transmission, vol 16. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8582-7_21
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8582-7_21
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-8584-1
Online ISBN: 978-3-7091-8582-7
eBook Packages: Springer Book Archive